Citius Oncology (CTOR) Debt to Equity (2021 - 2022)
Citius Oncology (CTOR) recorded quarterly Debt to Equity of $0.01 in Q3 2022, up 100.04% quarter-over-quarter from -$12.92 in Q4 2021.
Citius Oncology (CTOR) Debt to Equity (2021 - 2022) Analysis & Trends
Citius Oncology's Debt to Equity history runs 2 years deep, the most recent figure standing at $0.01 for Q3 2022.
- In Q3 2022, Debt to Equity changed N/A year-over-year to $0.01; the TTM figure through Sep 2022 stood at $0.01 (changed N/A YoY), while the FY2021 annual figure was -$12.92, changed N/A from the prior year.
- Debt to Equity was $0.01 for Q3 2022 at Citius Oncology, up from -$12.92 in the prior quarter.
- In the past five years, Debt to Equity ranged from a high of $0.01 in Q3 2022 to a low of -$12.92 in Q4 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Debt/Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 2.02 |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 2.80 |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | - |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | 0.01 |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | - |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 0.61 |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | 0.86 |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | - |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 0.47 |
| 10 | Citius Oncology | 71.02 Mn | 68.39 Mn | 1.34 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2022 | 0.01 |
| Dec 31, 2021 | -12.92 |